Skip to content

The association study of blood nutrients & metabolites and endometrial cancer

The accociation study of plasma Fatty Acids and recurrence of endometrial cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900025418
Enrollment
Unknown
Registered
2019-08-26
Start date
2012-12-31
Completion date
Unknown
Last updated
2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial cancer

Interventions

Case series:Nil

Sponsors

Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. A patient who underwent first uterine surgery at the Fudan University Cancer center and had no surgical contraindications; 2. A patient who signed an informed consent form and was willing to complete the study in accordance with the program; 3. The case group was diagnosed as endometrial cancer by pathology. The control group had no endometrial cancer after pathological diagnosis (endometrial atypical hyperplasia and normal endometrium with benign lesions to remove the uterus); 4. Aged 18-80 years old; 5. Clinical data (clinical diagnosis, pathological tissue staging, postoperative results, etc.) and follow-up data were complete.

Exclusion criteria

Exclusion criteria: 1) Those who have received radiotherapy or chemotherapy before surgery; 2) Those with a history of other malignant tumors, appropriate treatment of basal cells or squamous cell skin cancer, cervical carcinoma in situ or other cancer patients who have survived for more than 5 years can be enrolled; 3) Hyperglycemia patients whose drugs cannot be controlled, routine blood glucose >11.0mmol/L combined with clinical surgical pointers do not meet the surgical conditions; 4) thyroid dysfunction, TT3 (serum total T3) > 4.5nmol/L, TT4 (serum total thyroxine) >230nmol/L, FT4 (serum free thyroxine) >38pmol/L, FT3 (serum free T3) 17pmol/L, uTSH (supersensitive thyrotropin) <0.5 milliunits/liter. 5) Participate in another clinical trial within 30 days prior to randomization and receive study medication and any concomitant treatment with study medication; 6) Those with immunodeficiency or HIV infection; 7) severe heart, lung, liver and kidney dysfunction; 8) Uncontrolled infections or active infections; 9) pregnant, lactating women.

Design outcomes

Primary

MeasureTime frame
survivorship;

Countries

China

Contacts

Public ContactYing Gao

Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences

yinggao@sibs.ac.cn+86 021-54920985

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 27, 2026